Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7):1720–1748. https://doi.org/10.1038/s41375-022-01620-2

Azevedo LS, Pierrotti LC, Abdala E, Costa SF, Strabelli TM, Campos SV, Ramos JF, Latif AZ, Litvinov N, Maluf NZ, Caiaffa Filho HH, Pannuti CS, Lopes MH, Santos VA, Linardi Cda C, Yasuda MA, Marques HH (2015) Cytomegalovirus infection in transplant recipients. Clinics (Sao Paulo) 70(7):515–523. https://doi.org/10.6061/clinics/2015(07)09

Article  PubMed  Google Scholar 

Chan T, Champagne JN, Boudreault JS (2024) Efficacy and safety of bendamustine-rituximab as frontline therapy for indolent non-Hodgkin lymphoma: a real-world, single-center, retrospective study. Cureus 16(8):e66124. https://doi.org/10.7759/cureus.66124

Article  PubMed  PubMed Central  Google Scholar 

Cona A, Tesoro D, Chiamenti M, Merlini E, Ferrari D, Marti A, Codecà C, Ancona G, Tincati C, d’Arminio Monforte A, Marchetti G (2019) Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. BMC Infect Dis 19(1):881. https://doi.org/10.1186/s12879-019-4545-7

Article  PubMed  PubMed Central  Google Scholar 

Deans C, Wigmore SJ (2005) Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8(3):265–269. https://doi.org/10.1097/01.mco.0000165004.93707.88

Article  PubMed  Google Scholar 

Degli-Esposti MA, Hill GR (2022) Immune control of cytomegalovirus reactivation in stem cell transplantation. Blood 3(9):1277–1288. https://doi.org/10.1182/blood.2020010028

Article  Google Scholar 

Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM (2019) First-line treatment of patients with indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma with Bendamustine plus Rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol 37(12):984–991. https://doi.org/10.1200/JCO.18.00605

Article  PubMed  PubMed Central  Google Scholar 

Fowler NH (2011) Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma. Pharm Ther 36(9):590–598

Google Scholar 

Fujimura T, Yamashita-Kashima Y, Kawasaki N, Yoshiura S, Harada N, Yoshimura Y (2021) Obinutuzumab in combination with chemotherapy enhances direct cell death in CD20-positive obinutuzumab-resistant non-Hodgkin lymphoma cells. Mol Cancer Ther 20(6):1133–1141. https://doi.org/10.1158/1535-7163.MCT-20-0864

Article  PubMed  Google Scholar 

Fung M, Jacobsen E, Freedman A, Prestes D, Farmakiotis D, Gu X, Nguyen PL, Koo S (2019) Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis 68(2):247–255. https://doi.org/10.1093/cid/ciy458

Article  PubMed  Google Scholar 

Girmenia C, Lazzarotto T, Martino M, Bonifazi F, Baldanti F, Clerici P, Citterio F, De Carlis L, Barosi G, Grossi PA (2025) Management of cytomegalovirus infection in allogeneic hematopoietic stem cell and in solid organ transplantation: updated recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian societies. Clin Transpl 39(8):e70255. https://doi.org/10.1111/ctr.70255

Article  Google Scholar 

Hasegawa T, Aisa Y, Shimazaki K, Nakazato T (2015) Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma. Ann Hematol 94(3):515–517. https://doi.org/10.1007/s00277-014-2182-1

Article  PubMed  Google Scholar 

Hayashino K, Seike K, Masunari T, Hashida R, Oka S, Fujiwara Y, Terao T, Kitamura W, Kobayashi H, Kamoi C, Kondo T, Fujiwara H, Asada N, Ennishi D, Fujii K, Fujii N, Maeda Y (2025) Cytomegalovirus reactivation in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Int J Hematol. https://doi.org/10.1007/s12185-025-04023-y

Article  PubMed  PubMed Central  Google Scholar 

Herting F, Friess T, Bader S, Muth G, Hölzlwimmer G, Rieder N, Umana P, Klein C (2014) Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma 55(9):2151–5160. https://doi.org/10.3109/10428194.2013.856008

Article  PubMed  Google Scholar 

Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE (2018) Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 36(23):2395–2404. https://doi.org/10.1200/JCO.2017.76.8960

Article  PubMed  Google Scholar 

Hosoda T, Yokoyama A, Yoneda M, Yamamoto R, Ohashi K, Kagoo T, Ueno H, Boku S, Yano T (2013) Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma 54(6):1327–1328. https://doi.org/10.3109/10428194.2012.739285

Article  PubMed  Google Scholar 

Isono N, Imai Y, Watanabe A, Moriya K, Tamura H, Inokuchi K, Asano C, Masuda M, Shimura H, Mitsuhashi K, Kazama H, Sugimori H, Motoji T, Tanaka J (2016) Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. Leuk Lymphoma 57(9):2204–2207. https://doi.org/10.3109/10428194.2015.1126589

Article  PubMed  Google Scholar 

Ito K, Koseki T, Morisaku M, Yamada S, Hayakawa N (2024) Cytomegalovirus occurrence and time-to-onset analysis under bendamustine with anti-CD20 antibodies using the JADER database. In Vivo 38(2):923–927. https://doi.org/10.21873/invivo.13520

Article  PubMed  PubMed Central  Google Scholar 

Jacobsen E (2022) Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol 97(12):1638–1651. https://doi.org/10.1002/ajh.26737

Article  PubMed  Google Scholar 

Kampouri E, Ibrahimi SS, Xie H, Wong ER, Hecht JB, Sekhon MK, Vo A, Stevens-Ayers TL, Green DJ, Gauthier J, Maloney DG, Perez A, Jerome KR, Leisenring WM, Boeckh MJ, Hill JA (2024) Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy. Clin Infect Dis 10(4):1022–1032. https://doi.org/10.1093/cid/ciad708

Article  Google Scholar 

Karaman B, Dinçer G, Tunçel R, Ekmekci O, Yüceyar N (2025) Secondary hypogammaglobulinemia and lymphocytopenia in patients with inflammatory neurological diseases on anti-CD20 therapy: risk of infection and infection-related mortality. Neurol Sci 46(9):4569–4574. https://doi.org/10.1007/s10072-025-08329-x

Article  PubMed  PubMed Central  Google Scholar 

Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K (2019) Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood 133(2):137–146. https://doi.org/10.1182/blood-2018-04-848044

Article  PubMed  PubMed Central  Google Scholar 

Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T, Babic A (2022) Bendamustine: a review of pharmacology, clinical use and immunological effects (review). Oncol Rep 47(6):114. https://doi.org/10.3892/or.2022.8325

Article  PubMed  PubMed Central  Google Scholar 

Lara S, Heilig J, Virtanen A, Kleinau S (2022) Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma. BMC Cancer 22(1):678. https://doi.org/10.1186/s12885-022-09772-1

Article  PubMed  PubMed Central  Google Scholar 

Lim SH, Pathapati S, Langevin J, Hoot A (2012) Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol 91(4):643–644. https://doi.org/10.1007/s00277-011-1307-z

Article  PubMed  Google Scholar 

Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH, Sadowska-Klasa A, Navarro D, Styczynski J, de la Camara R (2025) Recommendations from the 10th European conference on infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis 25(8):e451–e462. https://doi.org/10.1016/S1473-3099(25)00069-6

Article  PubMed  Google Scholar 

Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN; 2017 European Conference on Infections in Leukaemia group (2019) Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 19(8):e260–e272. https://doi.org/10.1016/S1473-3099(19)30107-0

Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 5(14):1331–1344. https://doi.org/10.1056/NEJMoa1614598

Article  Google Scholar 

Modvig L, Boyle C, Randall K, Borg A (2017) Severe cytomegalovirus reactivation in patient with low-grade non-Hodgkin’s lymphoma after standard chemotherapy. Case Rep Hematol 2017:5762525. https://doi.org/10.1155/2017/5762525

Article  PubMed  PubMed Central  Google Scholar 

Ong DSY, Chong GM, Chemaly RF, Cremer OL (2022) Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression. Clin Microbiol Infect 28(10):1335–1344. https://doi.org/10.1016/j.cmi.2022.05.034

Article